Fort Worth-based NanOlogy, LLC, a clinical-stage oncology company, has named veteran biopharma executive David Arthur as its new chief executive officer.
Arthur becomes the company’s chief executive as NanOlogy moves toward later-stage development and commercialization. Founder H. Paul Dorman remains chairman.
The appointment comes as NanOlogy works to advance its Large Surface Area Microparticles (LSAM) drug portfolio, including a program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a rare and aggressive pediatric brain cancer with limited treatment options. For more details, see Dallas Innovates.
